AKTX - Akari Therapeutics, Plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development11,795.37623,285.27917,306.0015,799.076
Selling General and Administrative10,896.15811,798.919,940.5575,502.214
Non Recurring----
Others----
Total Operating Expenses22,691.53435,084.18927,246.55811,301.29
Operating Income or Loss-22,691.534-35,084.189-27,246.558-11,301.29
Income from Continuing Operations
Total Other Income/Expenses Net6,224.754-315.0689,105.561-34,016.242
Earnings Before Interest and Taxes-22,691.534-35,084.189-27,246.558-11,301.29
Interest Expense----3,053.948
Income Before Tax-16,466.78-35,399.257-18,140.997-45,317.532
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-16,466.78-35,399.257-18,140.997-45,317.532
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-16,466.78-35,399.257-18,140.997-45,317.532
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-16,466.78-35,399.257-18,140.997-45,317.532